German Federal Fiscal Court held that mandatory pharmaceutical rebates must be split into net and VAT components

Germany enforces strict, uniform list prices for prescription drugs (inter alia, to protect the margins of pharmacies and to maintain a perceived benchmark status for reference pricing). Instead of legally lowering the official list prices - which would trigger an immediate domino effect of price drops for pharmaceutical manufacturers - German law dictates that manufacturers must grant mandatory, retrospective rebates to statutory and private health insurance funds.

In the underlying case, a pharmaceutical company argued that these mandatory retrospective rebates should be entirely excluded from the VAT taxable amount of the corresponding transaction. For instance, if a rebate of EUR119 was paid to a health insurance fund, the company sought to reduce its taxable basis by EUR119, thereby maximising VAT reduction.

The BFH dismissed this approach, referencing Court of Justice of the European Union (CJEU) case law. The BFH argued that under EU VAT principles, the taxable amount is the consideration actually received, excluding VAT. Therefore, a subsequent rebate paid to a third party (the health insurance fund) is legally assumed to be a reduction of the VAT inclusive transaction price. Consequently, any mandatory rebate paid must be mathematically split into a net price reduction and a corresponding VAT adjustment. A EUR119 rebate must be viewed as a EUR100 reduction of the taxable basis and a EUR19 VAT adjustment.

Key takeaway

Pharmaceutical companies, wholesalers, and distributors operating in Germany must review their ERP, invoicing, and tax compliance systems. Booking mandatory health insurance rebates as VAT exclusive amounts is contrary to the BFH view. The German tax authorities will likely enforce the “gross-net split” during tax audits. Systemic non-compliance in this highly regulated sector carries severe risks of substantial VAT reassessments and significant interest penalty payments.

Reference

German Federal Fiscal Court (BFH), Order of 14 January 2026; CJEU case law principles